Payment overview · 2025
General Payments
$5,998.52
51 reported records · 5 companies
Healthcare provider profile · identity verified
David E Schleinkofer, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · FORT WAYNE, IN · NPI 1326030297
Verified facts
What the public records show
CMS Open Payments records show David E Schleinkofer, MD received $5,998.52 in general payments during 2025 across 51 reported records.
BIOTRONIK INC. accounted for 44.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $2,643.80 | 44.1% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,732.85 | 28.9% | 17 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,586.14 | 26.4% | 22 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.92 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.81 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $4,785.57 | 15 |
| Food and Beverage | $1,212.95 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $1,393.22 | 12 | 2025 |
Source payment records
|
|||||
| EVERA MRI XT DR SURESCAN Normalized: evera mri xt dr surescan |
Device | Medtronic, Inc. | $1,378.39 | 9 | 2025 |
Source payment records
|
|||||
| Selectra Normalized: selectra |
Device | BIOTRONIK INC. | $1,290.42 | 2 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $1,290.42 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $110.16 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $98.68 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $88.51 | 2 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $56.83 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $55.03 | 5 | 2025 |
Source payment records
|
|||||
| TENDRIL Normalized: tendril |
Device | Abbott Laboratories | $38.60 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $35.36 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $15.96 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $11.78 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $2.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
71 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1067 | 285 |
| Metoprolol Succinate | Metoprolol Succinate | 640 | 223 |
| Carvedilol | Carvedilol | 490 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 139 |
| Losartan Potassium | Losartan Potassium | 388 | 122 |
| Amiodarone Hcl | Amiodarone Hcl | 385 | 133 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 385 | 123 |
| Furosemide | Furosemide | 380 | 139 |
| Metoprolol Tartrate | Metoprolol Tartrate | 370 | 124 |
| Lisinopril | Lisinopril | 316 | 108 |
| Xarelto | Rivaroxaban | 277 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 70 |
| Spironolactone | Spironolactone | 222 | 69 |
| Atenolol | Atenolol | 220 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 204 | 65 |
| Flecainide Acetate | Flecainide Acetate | 166 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 52 |
| Nitroglycerin | Nitroglycerin | 159 | 98 |
| Potassium Chloride | Potassium Chloride | 137 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 52 |
| Dofetilide | Dofetilide | 124 | 45 |
| Corlanor | Ivabradine Hcl | 123 | 26 |
| Midodrine Hcl | Midodrine Hcl | 117 | 46 |
| Propafenone Hcl | Propafenone Hcl | 115 | 44 |
| Cephalexin | Cephalexin | 93 | 92 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 28 |
| Torsemide | Torsemide | 79 | 30 |
| Valsartan | Valsartan | 74 | 28 |
| Entresto | Sacubitril/Valsartan | 71 | 24 |
| Sotalol | Sotalol Hcl | 67 | 19 |
| Propranolol Hcl | Propranolol Hcl | 63 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 55 | 12 |
| Bumetanide | Bumetanide | 53 | 20 |
| Ezetimibe | Ezetimibe | 53 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 23 |
| Verapamil Er | Verapamil Hcl | 50 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 17 |
| Digoxin | Digoxin | 46 | 14 |
| Nifedipine Er | Nifedipine | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | 18 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Multaq | Dronedarone Hcl | 35 | suppressed |
| Praluent Pen | Alirocumab | 35 | suppressed |
| Ivabradine Hcl | Ivabradine Hcl | 33 | 16 |
| Ramipril | Ramipril | 33 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | 17 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 30 | suppressed |
| Metolazone | Metolazone | 28 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 23 | 17 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 21 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,998.52 · 51 records | BIOTRONIK INC. | AFFERA MAPPING SYSTEM, ASSURITY, AURORA EV-ICD MRI SURESCAN, AVEIR, Acticor 7 VR-T DX, BIOMONITOR, COBALT DR MRI SURESCAN, ENSITE PRECISION, EVERA MRI XT DR SURESCAN, GALLANT, JOT DX, LEQVIO, LINQ II, MICRA, SELECTSECURE, Selectra, Solia, TENDRIL, VERQUVO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error